- Home
- BIRD vs ATRA Comparison
BIRD vs ATRA Comparison
Compare BIRD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | ATRA |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 37.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BIRD | ATRA |
|---|---|---|
| Price | $3.96 | $5.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.00 | $6.00 |
| AVG Volume (30 Days) | 47.9K | ★ 717.8K |
| Earning Date | 03-10-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | ★ $160,639,000.00 | $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.03 | N/A |
| P/E Ratio | ★ N/A | $2.80 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | $3.83 | $4.20 |
| 52 Week High | $12.85 | $19.15 |
Technical Indicators
Market Signals| Indicator | BIRD | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 31.30 |
| Support Level | $3.87 | $4.20 |
| Resistance Level | $4.15 | $5.71 |
| Average True Range (ATR) | 0.23 | 0.92 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 20.50 | 10.82 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).